Evidence map›Paper›PMID 31155953›Full record

Trial reportNutrition and cancer2020

Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.

Zhenzhen Zhang, Mark Garzotto, Edward W Davis, Motomi Mori, Wesley A Stoller, Paige E Farris, Carmen P Wong, Laura M Beaver, George V Thomas, David E Williams and 4 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrition and cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Zhenzhen ZhangDivision of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Mark GarzottoDepartment of Urology, Portland Veterans Administration Medical Center, Oregon Health & Science University, Portland, Oregon, USA.
Edward W DavisSchool of Biological and Population Health Science, Oregon State University, Corvallis, Oregon, USA.
Motomi MoriDivision of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Wesley A StollerDivision of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Paige E FarrisDivision of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Carmen P WongSchool of Biological and Population Health Science, Oregon State University, Corvallis, Oregon, USA.
Laura M BeaverSchool of Biological and Population Health Science, Oregon State University, Corvallis, Oregon, USA.
George V ThomasKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
David E WilliamsLinus Pauling Institute, Oregon State University, Corvallis, Oregon, USA.
Roderick H DashwoodCenter for Epigenetics & Disease Prevention, Texas A&M College of Medicine, Houston, Texas, USA.
David A HendrixDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA.
Emily HoSchool of Biological and Population Health Science, Oregon State University, Corvallis, Oregon, USA.
Jackilen ShannonDivision of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Oregon Health & Science University · USOregon State University · USPortland VA Medical Center · US

Funding

Transplacental Chemoprevention of Lung Tumors and LymphomasP01CA090890 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2003 to 2014
$14.2M
NCI NIH HHS P01 CA090890
6 · The paper itself

Abstract

Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development,

Indexed as

BrassicaAgedAnticarcinogenic AgentsBiological AvailabilityBiomarkers, TumorBiopsyChemopreventionCyclin-Dependent Kinase Inhibitor p21Double-Blind MethodHistone DeacetylasesHumansIsothiocyanatesKi-67 AntigenMaleMiddle AgedProstatealpha-methylacyl-CoA racemaseAnticarcinogenic AgentsBiomarkers, TumorCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Histone DeacetylasesIsothiocyanatesKi-67 AntigenMKI67 protein, humanRacemases and EpimerasessulforaphaneSulfoxides

Identifiers

PMID31155953
PMCPMC8244813
OpenAlexW2946924428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.